Skip to content
Calculator
Guide

Compounded, branded or "research" tirzepatide: identity, purity and law side by side

Last updated: October 27, 2026 · 6 min read · By the Grey Peptides Editorial Board

A pharmacy shelf lined with old medicine bottles and boxes
Photo by Magda Ehlers on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Only branded tirzepatide, Mounjaro and Zepbound, is FDA-approved and made under an approved application 1. Compounded tirzepatide is not FDA-approved, and "research" tirzepatide is not a medicine at all in the eyes of the FDA.
  • Since the shortage ended, the room for compounding has narrowed: the FDA's grace periods for copies ran out in February and March 2025, it proposed in May 2026 to keep tirzepatide off the outsourcing-facility list, and in September 2026 it warned a compounding pharmacy that its vitamin-added versions appear to be essentially copies of the approved drugs 3 6 8.
  • "Research use only" labels do not protect sellers: five FDA warning letters dated August 24, 2026 called such products unapproved new drugs 11. The one published test purchase of online GLP-1 vials, of semaglutide, found semaglutide made up only 7.7% to 14.4% of the powder in each vial and measured endotoxin at 8.95 EU/mg in one vial 12.

The three supply chains side by side (as of October 27, 2026)

BrandedCompounded"Research"
FDA-approvedYes: Mounjaro (2022), Zepbound (2023)NoNo
Who checks identity and purityThe manufacturer, against an FDA-approved applicationThe compounding pharmacy or outsourcing facility, under pharmacy rules, not an approved applicationNobody independent; at most a certificate the seller supplies
PrescriptionRequiredRequired for a patientNone
Legal positionApproved drugCopies restricted since the shortage ended; 503B route proposed closedCalled unapproved new drugs in FDA warning letters

The rest of this page sets out where each row comes from.

Branded: Mounjaro and Zepbound

Tirzepatide High is approved in the US as Mounjaro for type 2 diabetes, since May 13, 2022, and as Zepbound for weight management, since November 8, 2023, both Eli Lilly applications 1. Approval means the FDA reviewed the manufacturer's evidence and its manufacturing, and the product carries a label with its doses, warnings and interactions; the current Zepbound label, effective August 28, 2026, for example, tells users of oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase 2.

Compounded tirzepatide

Pharmacies were allowed to make copies of tirzepatide while it was on the FDA's drug shortage list, which it joined on December 15, 2022 3. On December 19, 2024, the FDA issued a declaratory order finding the shortage resolved and set end dates for its enforcement discretion: February 18, 2025 for state-licensed pharmacies compounding under section 503A, and March 19, 2025 for outsourcing facilities under section 503B 3. Since then, a law firm's reading is that a 503A pharmacy may not compound what is essentially a copy of the commercially available drug, and can still compound tirzepatide only in a narrow set of circumstances, "such as documentation of medical necessity" 4. A 503B facility needs the drug to be on the shortage list or on the 503B bulks list 4 5. In a notice published in the Federal Register on May 1, 2026, the FDA proposed not to add tirzepatide, semaglutide or liraglutide to that list (91 FR 23431); it extended the comment period to July 30, 2026, and at our check on October 27, 2026 it had published no final decision 6 7.

The FDA has also rejected a workaround of adding an ingredient. In a warning letter dated September 18, 2026, it told a Houston compounding pharmacy that its semaglutide and tirzepatide products, including tirzepatide with niacinamide, appear to be essentially copies of the FDA-approved products, noting prescribers' "significant difference" statements repeated verbatim across many records and that "the volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual" 8.

On safety, the evidence is a signal rather than a measurement. A study of the FDA's adverse event reporting system from 2018 to 2024 found 707 reports involving compounded GLP-1 drugs out of 81,078. Compared with branded products, compounded ones had higher reporting odds of preparation errors, contamination, manufacturing issues and hospitalization (odds ratio 2.35), and lower reporting odds of administration and dosing errors 9. Reporting odds show which problems are reported more often, not how often they happen.

"Research" tirzepatide

The third channel sells tirzepatide powder in vials labelled "for research purposes only" or "not for human consumption", without a prescription. A 2024 commentary by pharmacy researchers notes that buyers often receive the vial without the supplies or knowledge needed to dissolve, draw up and inject it, and that skipping the prescriber removes the checks for interactions and monitoring 10.

The FDA does not accept the label at face value. Its warning letters dated August 24, 2026 to five online sellers listed tirzepatide products among those they covered, called them unapproved new drugs, and said that labelling the products for laboratory or research use, and not for human use, did not outweigh what the sellers' own websites showed; one letter quotes the labels 'for laboratory, research, and analytical use' and 'not intended for human or veterinary use' 11.

What is in such vials has rarely been tested independently. The one published test purchase of online GLP-1 vials we found concerns semaglutide, not tirzepatide: the three vials delivered held 28.6% to 38.7% more semaglutide than labelled, yet semaglutide made up only 7.7% to 14.4% of the powder in each vial, against sellers' claims of at least 99% purity, a different measure; endotoxin was measured at 8.95 EU/mg in one vial, and the other two were reported only as below 2.9 and 2.2 EU/mg 12. A certificate of analysis supplied by a seller is not the same as a regulator's check; our COA Decoder explains what one can and cannot show.

What this means in practice

Branded tirzepatide is the only version made under an FDA-approved application 1. Compounded tirzepatide may still be prescribed in limited cases, but the legal room has narrowed since the shortage ended, and the FDA's proposal on the 503B list is still pending 6 7. "Research" tirzepatide is, in the FDA's letters, an unapproved new drug 11; those letters were aimed at the sellers, and the risk of what is in the vial falls on the person who injects it. For anyone losing access to a compounded GLP-1, our GLP-1 transition guide covers the options.

Frequently asked questions

Is compounded tirzepatide still legal?

Only in narrow cases. Since the FDA found the shortage resolved on December 19, 2024, pharmacies may not compound essentially copies of the approved drug; the grace periods ended on February 18, 2025 (503A) and March 19, 2025 (503B). A law firm's reading is that a 503A pharmacy can still compound it in narrow circumstances, such as documented medical necessity.

Is compounded tirzepatide the same as Zepbound?

It is meant to contain the same active ingredient but is not FDA-approved, and it is not made under an approved application. In a September 2026 warning letter the FDA said a pharmacy's tirzepatide with added niacinamide appeared to be essentially a copy of the approved product.

Is research tirzepatide safe?

Nothing independent verifies what is in it. The FDA called such products unapproved new drugs in August 2026, and the one published test purchase of online GLP-1 vials, of semaglutide, found semaglutide made up only 7.7% to 14.4% of the powder in each vial and measured endotoxin at 8.95 EU/mg in one vial.

What is the 503B proposal?

On May 1, 2026, the FDA proposed not to add tirzepatide, semaglutide or liraglutide to the list of substances outsourcing facilities can compound from. The comment period was extended to July 30, 2026; at our check on October 27, 2026, no final decision had been published.

Sources

  1. US FDA. Drugs@FDA via openFDA: NDA215866 (Mounjaro, Eli Lilly), original approval May 13, 2022; NDA217806 (Zepbound, Eli Lilly), original approval November 8, 2023. Read October 27, 2026.
  2. Eli Lilly. Zepbound (tirzepatide) US prescribing information, sections 7.2 and 8.3 (DailyMed set 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, effective August 28, 2026); read October 2, re-read October 27, 2026. DailyMed
  3. US FDA. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound), December 19, 2024; read October 2, re-read October 27, 2026. FDA
  4. Frier Levitt (law firm). FDA Determines (Again) the Tirzepatide Shortage Is Resolved: What This Means for 503A and 503B Compounding, January 9, 2025. A law firm's analysis, not an FDA document. Read October 2, re-read October 27, 2026. Cited without a link.
  5. 21 U.S.C. 353b(a)(2)(A): an outsourcing facility may compound from a bulk drug substance only if it is on the list of substances for which there is a clinical need or the drug is on the drug shortage list. Text read October 27, 2026 (Legal Information Institute). Cited without a link.
  6. US FDA. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (press announcement, April 30, 2026; content current as of April 30, 2026). Read October 27, 2026. FDA
  7. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B: notice of May 1, 2026 (91 FR 23431) and extension of comment period to July 30, 2026 (91 FR 38719, June 26, 2026); no later document on the proposal found October 27, 2026. Federal Register
  8. US FDA. Warning letter to a Houston compounding pharmacy (semaglutide and tirzepatide products, including tirzepatide with niacinamide), September 18, 2026, posted September 22, 2026; read October 2, re-read October 27, 2026. FDA
  9. McCall, K. L., et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf, 25(3), 581-588. PMID: 40285721 · doi:10.1080/14740338.2025.2499670
  10. Belcourt, J., et al. (2025). Bypassing Prescribers and Pharmacists: Online Purchasing of Semaglutide and Tirzepatide "For Research Purposes". Ann Pharmacother, 59(5), 485-490. PMID: 39285774 · doi:10.1177/10600280241277551
  11. US FDA. Warning letters dated August 24, 2026 to five online peptide sellers, posted September 1, 2026 (one linked; letter 733652 and three others re-read October 27, 2026, three of them naming tirzepatide); read October 2, 2026. FDA
  12. Ashraf, A. R., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 26, e65440. PMID: 39509151 · doi:10.2196/65440

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead